temozolomide has been researched along with Minimal Disease, Residual in 12 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the effect and toxicity of hypofractionated high-dose intensity modulated radiation therapy (IMRT) with concurrent and adjuvant temozolomide (TMZ) in 46 patients with newly diagnosed glioblastoma multiforme (GBM)." | 9.19 | Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma. ( Hara, R; Hasegawa, Y; Hatano, K; Iuchi, T; Kawasaki, K; Kodama, T; Sakaida, T; Yokoi, S, 2014) |
| "To determine the maximal tolerated biologic dose intensification of radiotherapy using fractional dose escalation with temozolomide (TMZ) chemotherapy in patients with newly diagnosed glioblastoma multiforme." | 9.15 | Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme. ( Chen, C; Damek, D; Gaspar, LE; Kavanagh, BD; Kleinschmidt-DeMasters, BK; Lillehei, K; Robischon, M; Rusthoven, KE; Stuhr, K; Waziri, A, 2011) |
| "Standard-of-care treatment of glioblastomas involves maximal safe resection and adjuvant temozolomide chemo-radiotherapy." | 7.91 | Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: A multicenter cohort study. ( Chan, DTM; Chan, KY; Ho, JMK; Lam, SW; Lee, MWY; Mak, CHK; Poon, WS; Tse, TPK; Wong, ST; Woo, PYM, 2019) |
| "It is currently unclear whether adjuvant therapy for WHO grade III anaplastic astrocytomas (AA) should be carried out as combined chemoradiotherapy with temozolomide (TMZ)--analogous to the approach for glioblastoma multiforme--or as radiotherapy (RT) alone." | 7.81 | Adjuvant temozolomide-based chemoradiotherapy versus radiotherapy alone in patients with WHO III astrocytoma: The Mainz experience. ( Giese, A; Mayer, A; Renovanz, M; Schmidberger, H; Schwanbeck, C; Sommer, C; Stockinger, M; Vaupel, P, 2015) |
| "The prognostic value of postoperative residual tumor volume in FET PET, TBR(mean,) TBR(max) and Gd-volume was evaluated using Kaplan-Maier estimates for disease-free survival (DFS) and overall survival (OS)." | 5.37 | Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy. ( Coenen, HH; Eble, MJ; Galldiks, N; Herzog, H; Holy, R; Kaiser, HJ; Langen, KJ; Pinkawa, M; Piroth, MD; Stoffels, G, 2011) |
| "To assess the effect and toxicity of hypofractionated high-dose intensity modulated radiation therapy (IMRT) with concurrent and adjuvant temozolomide (TMZ) in 46 patients with newly diagnosed glioblastoma multiforme (GBM)." | 5.19 | Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma. ( Hara, R; Hasegawa, Y; Hatano, K; Iuchi, T; Kawasaki, K; Kodama, T; Sakaida, T; Yokoi, S, 2014) |
| "To determine the maximal tolerated biologic dose intensification of radiotherapy using fractional dose escalation with temozolomide (TMZ) chemotherapy in patients with newly diagnosed glioblastoma multiforme." | 5.15 | Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme. ( Chen, C; Damek, D; Gaspar, LE; Kavanagh, BD; Kleinschmidt-DeMasters, BK; Lillehei, K; Robischon, M; Rusthoven, KE; Stuhr, K; Waziri, A, 2011) |
| "Standard-of-care treatment of glioblastomas involves maximal safe resection and adjuvant temozolomide chemo-radiotherapy." | 3.91 | Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: A multicenter cohort study. ( Chan, DTM; Chan, KY; Ho, JMK; Lam, SW; Lee, MWY; Mak, CHK; Poon, WS; Tse, TPK; Wong, ST; Woo, PYM, 2019) |
| "It is currently unclear whether adjuvant therapy for WHO grade III anaplastic astrocytomas (AA) should be carried out as combined chemoradiotherapy with temozolomide (TMZ)--analogous to the approach for glioblastoma multiforme--or as radiotherapy (RT) alone." | 3.81 | Adjuvant temozolomide-based chemoradiotherapy versus radiotherapy alone in patients with WHO III astrocytoma: The Mainz experience. ( Giese, A; Mayer, A; Renovanz, M; Schmidberger, H; Schwanbeck, C; Sommer, C; Stockinger, M; Vaupel, P, 2015) |
| "Temozolomide was administered twice daily on days -10 to -6, followed by thiotepa 300 mg/m(2) per day and carboplatin dosed using the Calvert formula or body surface area on days -5 to -3, with AHCR day 0." | 2.82 | Phase I study of temozolomide in combination with thiotepa and carboplatin with autologous hematopoietic cell rescue in patients with malignant brain tumors with minimal residual disease. ( Belasco, JB; Cervone, KA; Egan, G; Finlay, JL; Gardner, SL; Philips, PC, 2016) |
| "Pathology was anaplastic oligodendroglioma (AOD) and anaplastic astrocytoma IDH-mutated (AAmut) in 32 and 21 patients respectively." | 1.51 | Tumour volume reduction following PET guided intensity modulated radiation therapy and temozolomide in IDH mutated anaplastic glioma. ( Back, M; Bailey, D; Brazier, D; Guo, L; Hsiao, E; Jayamanne, D; Wheeler, H, 2019) |
| "The prognostic value of postoperative residual tumor volume in FET PET, TBR(mean,) TBR(max) and Gd-volume was evaluated using Kaplan-Maier estimates for disease-free survival (DFS) and overall survival (OS)." | 1.37 | Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy. ( Coenen, HH; Eble, MJ; Galldiks, N; Herzog, H; Holy, R; Kaiser, HJ; Langen, KJ; Pinkawa, M; Piroth, MD; Stoffels, G, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 10 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ellingson, BM | 1 |
| Abrey, LE | 1 |
| Nelson, SJ | 1 |
| Kaufmann, TJ | 1 |
| Garcia, J | 1 |
| Chinot, O | 1 |
| Saran, F | 1 |
| Nishikawa, R | 1 |
| Henriksson, R | 1 |
| Mason, WP | 1 |
| Wick, W | 1 |
| Butowski, N | 1 |
| Ligon, KL | 1 |
| Gerstner, ER | 1 |
| Colman, H | 1 |
| de Groot, J | 1 |
| Chang, S | 1 |
| Mellinghoff, I | 1 |
| Young, RJ | 1 |
| Alexander, BM | 1 |
| Colen, R | 1 |
| Taylor, JW | 1 |
| Arrillaga-Romany, I | 1 |
| Mehta, A | 1 |
| Huang, RY | 1 |
| Pope, WB | 1 |
| Reardon, D | 1 |
| Batchelor, T | 1 |
| Prados, M | 1 |
| Galanis, E | 1 |
| Wen, PY | 1 |
| Cloughesy, TF | 1 |
| Back, M | 1 |
| Jayamanne, D | 1 |
| Brazier, D | 1 |
| Bailey, D | 1 |
| Hsiao, E | 1 |
| Guo, L | 1 |
| Wheeler, H | 1 |
| Woo, PYM | 1 |
| Ho, JMK | 1 |
| Tse, TPK | 1 |
| Lam, SW | 1 |
| Mak, CHK | 1 |
| Chan, DTM | 1 |
| Lee, MWY | 1 |
| Wong, ST | 1 |
| Chan, KY | 1 |
| Poon, WS | 1 |
| Iuchi, T | 1 |
| Hatano, K | 1 |
| Kodama, T | 1 |
| Sakaida, T | 1 |
| Yokoi, S | 1 |
| Kawasaki, K | 1 |
| Hasegawa, Y | 1 |
| Hara, R | 1 |
| Mayer, A | 1 |
| Schwanbeck, C | 1 |
| Sommer, C | 1 |
| Stockinger, M | 1 |
| Giese, A | 1 |
| Renovanz, M | 1 |
| Vaupel, P | 1 |
| Schmidberger, H | 1 |
| Egan, G | 1 |
| Cervone, KA | 1 |
| Philips, PC | 1 |
| Belasco, JB | 1 |
| Finlay, JL | 1 |
| Gardner, SL | 1 |
| Alameda Hernando, C | 1 |
| Lahera Vargas, M | 1 |
| Varela Da Costa, C | 1 |
| Chen, C | 1 |
| Damek, D | 1 |
| Gaspar, LE | 1 |
| Waziri, A | 1 |
| Lillehei, K | 1 |
| Kleinschmidt-DeMasters, BK | 1 |
| Robischon, M | 1 |
| Stuhr, K | 1 |
| Rusthoven, KE | 1 |
| Kavanagh, BD | 1 |
| Piroth, MD | 1 |
| Holy, R | 1 |
| Pinkawa, M | 1 |
| Stoffels, G | 1 |
| Kaiser, HJ | 1 |
| Galldiks, N | 1 |
| Herzog, H | 1 |
| Coenen, HH | 1 |
| Eble, MJ | 1 |
| Langen, KJ | 1 |
| Kanold, J | 1 |
| Paillard, C | 1 |
| Tchirkov, A | 1 |
| Lang, P | 1 |
| Kelly, A | 1 |
| Halle, P | 1 |
| Isfan, F | 1 |
| Merlin, E | 1 |
| Marabelle, A | 1 |
| Rochette, E | 1 |
| Deméocq, F | 1 |
| Salvati, M | 1 |
| Piccirilli, M | 1 |
| Caroli, E | 1 |
| Brogna, C | 1 |
| Artizzu, S | 1 |
| Frati, A | 1 |
| Mineo, JF | 1 |
| Bordron, A | 1 |
| Baroncini, M | 1 |
| Ramirez, C | 1 |
| Maurage, CA | 1 |
| Blond, S | 1 |
| Dam-Hieu, P | 1 |
1 review available for temozolomide and Minimal Disease, Residual
| Article | Year |
|---|---|
[Treatment of clinically nonfunctioning pituitary adenomas].
Topics: Adenoma; Adult; Cranial Irradiation; Dacarbazine; Decompression, Surgical; Dopamine Agonists; Female | 2010 |
4 trials available for temozolomide and Minimal Disease, Residual
| Article | Year |
|---|---|
Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Contrast Media; Female; Follow-Up | 2018 |
Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cause of Death; Chemotherapy, Adjuvant; D | 2014 |
Phase I study of temozolomide in combination with thiotepa and carboplatin with autologous hematopoietic cell rescue in patients with malignant brain tumors with minimal residual disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Autografts; Brain Neoplasms; Carb | 2016 |
Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2011 |
7 other studies available for temozolomide and Minimal Disease, Residual
| Article | Year |
|---|---|
Tumour volume reduction following PET guided intensity modulated radiation therapy and temozolomide in IDH mutated anaplastic glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Humans; | 2019 |
Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: A multicenter cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Cohort Stu | 2019 |
Adjuvant temozolomide-based chemoradiotherapy versus radiotherapy alone in patients with WHO III astrocytoma: The Mainz experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chemoradi | 2015 |
Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Contrast | 2011 |
NK cell immunotherapy for high-risk neuroblastoma relapse after haploidentical HSCT.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Bone Marrow Neoplasms | 2012 |
Treatment of glioblastoma multiforme in the elderly in functionally non-critical areas. Clinical remarks on 22 patients.
Topics: Aged; Aged, 80 and over; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Neoplasm | 2003 |
Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modali | 2007 |